// App-Quantinova.ai

333 : Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Researchers

Presenter

  • Othon Iliopoulos

Principal Investigators

  • Eric Jonasch

  • Frede Donskov

  • Vivek Narayan

  • Benjamin Louis Maughan

  • Stephane Oudard

  • Tobias Else

  • Jodi K. Maranchie

  • Sarah J. Welsh

  • Sanjay Thamake

  • Rodolfo F. Perini

  • Eric Kristopher Park

  • W. Marston Linehan

  • Ramaprasad Srinivasan

  • W. Kimryn Rathmell

Medical Centers

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Aarhus University Hospital, Aarhus, Denmark

  • University of Pennsylvania, Philadelphia, PA

  • University of Utah, Salt Lake City, UT

  • Hopital European Georges Pompidou, Paris, France

  • University of Michigan, Ann Arbor, MI

  • University of Pittsburgh, Pittsburgh, PA

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ

  • National Cancer Institute, Bethesda, MD

  • Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • Vanderbilt University, Nashville, TN

Locations

  • United States

  • Denmark

  • France

  • United Kingdom

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

Biomarkers

  • Transthyretin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03401788

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved